Intravenous ferric carboxymaltose reduced the hospitalization burden in stabilized, iron-deficient patients who had acute HF with reduced ejection fraction in a placebo-controlled, randomized trial.
Iron deficiency, common in heart failure (HF), is associated with functional impairment and other adverse outcomes, even in the absence of anemia. Intravenous ferric carboxymaltose has been shown to improve symptoms, functional capacity, and health status in patients with chronic HF. The manufacturer-funded AFFIRM-AHF trial (NCT02937454) explored this treatment's potential benefit in patients stabilized after hospitalization for acute HF.
Researchers randomized 1108 hospitalized patients (mean age, 71; 45% women) with acute HF, left-ventricular ejection fraction (EF) <50% (mean, 33%), iron deficiency, and elevated brain-type natriuretic peptide levels to receive intravenous ferric carboxymaltose or placebo shortly before discharge and again …
Reviewing Author
DisclosuresConsultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research
Grant/Research SupportNational Heart, Lung, and Blood Institute
Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)
Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)
DisclosuresConsultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research
Grant/Research SupportNational Heart, Lung, and Blood Institute
Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)
Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)